In keeping with these data, the malaria VLP-based vaccine (Malarivax) [75–77] composed of HBc-Ag expressing P. falciparum T cell and B-cell epitopes identified from the circumsporozoite protein developed long-lasting immunity, eliciting a CD4+ T-cell immune response and is currently undergoing a clinical trial [15, 78, 79]. The gene discussed is CD4; the disease is malaria.